Table 7.

Association Between Anthracycline Chemotherapy vs Nonanthracycline Chemotherapy and Cause-Specific Mortality Among Patients With Pre-Existing HF

	HR (95% CI)
	Lymphoma Mortality	Cardiovascular Mortality	Nonlymphoma Cancer Mortality	Non-CV, Noncancer Mortality
Cohort sample size	245	245	245	245
Number of events	88	49	15	40
Unadjusteda	0.51 (0.32-0.80)	0.60 (0.35-1.04)	0.47 (0.17-1.32)	0.47 (0.24-0.91)
Model A (adjusted for clinical variables)b	0.44 (0.28-0.71)	0.62 (0.33-1.15)	0.44 (0.15-1.32)	0.36 (0.18-0.74)

Cox proportional hazards model using competing risks for 4 different cause-specific mortalities. Patients without pre-existing HF were excluded. Patients not receiving any chemotherapy in the first 90 days were excluded. Cancer treatment was modeled as a time-varying covariate in the first 90 days.

Abbreviations as in Tables 2 and 5.

^aUnadjusted includes anthracycline use within the first 90 days (time varying) as the only independent variable.

^bAdjusted for age, sex, Hispanic ethnicity, advanced stage (III or IV vs I or II), diabetes, any prior cancer diagnosis, chronic bronchitis/emphysema, dementia, and moderate or severe renal dysfunction and stratified by race.